Evaluating 68Ga-PSMA PET for advanced renal cancer diagnosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the diagnostic effectiveness of 68Ga-PSMA PET imaging in identifying metastatic lesions in patients with locally advanced and advanced renal cell carcinoma. It will compare the results of PSMA PET with those obtained from enhanced CT scans. Additionally, the study will investigate whether the use of 68Ga-PSMA PET can influence treatment decisions for these patients. Participants will undergo imaging within six weeks of their diagnosis to ensure timely evaluation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 2017 AJCC renal cell carcinoma TNM stage III, IV lesions;
* In contrast-enhanced CT staging, suspicious metastases were found;
* There were no known peripheral or central venous problems;
* 68Ga PSMA PET / CT imaging can be performed within 6 weeks after the diagnosis of renal cell carcinoma;
* Signed the informed consent form of voluntary participation in clinical trials.

Exclusion Criteria:

* Age ≤ 18 years old;
* Can't stand lying flat in PET / CT examination;
* There are contraindications for 68Ga PSMA ligands;
* In the past two years, there was a history of other malignant tumors, or according to the doctor's research judgment, complications may occur and affect the normal operation of the test;
* Renal function is impaired or hemodialysis is in progress.

Where it's running

• The First Hospital of Lanzhou University
  Lanzhou, Gansu, China Recruiting
• General Hospital of Ningxia Medical University
  Yinchuan, Ningxia, China Recruiting
• Qinghai University Affiliated Hospital
  Xining, Qinghai, China Recruiting
• Xijing Hospital
  Xi'an, Shaan'xi, China Recruiting
• Weinan Central Hospital
  Weinan, Shaanxi, China Recruiting
• Shaanxi Provincial People's Hospital
  Xi'an, Shaanxi, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Irreversible Electroporation for Recurrent Pelvic Tumors

  This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT07782164

• Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance

  This registry collects data from adults undergoing image-guided, minimally invasive cancer treatments to see if spectral angio-CT guidance helps predict outcomes and improve planning.

  Recruiting Leiden University Medical Center · Lyon, Auvergne-Rhône-Alpes and 2 other locations · NCT07636148

• LATTICE radiotherapy vs moderately dose-escalated palliative radiation for metastases

  This study tests whether LATTICE radiotherapy given in 5 fractions works better than a standard palliative dose for patients with metastatic cancer who have 1–2 sizable tumors.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT07594431

• Repeated PSMA PET scans to monitor treatment response in clinically significant prostate cancer.

  This project will test whether doing a PSMA PET/CT before treatment and again after treatment (or at early PSA rise) helps track response in people with newly diagnosed clinically significant (Gleason ≥7) prostate cancer.

  Recruiting at 9 sites Xijing Hospital · Lanzhou, Gansu and 8 other locations · NCT07553780

• Blood exosomal RNA test to rule out prostate cancer spread to bone

  This project will try a blood-based exosomal RNA test to see if it can rule out bone metastasis in people with newly diagnosed, treatment‑naïve prostate cancer scheduled for baseline PSMA PET.

  Recruiting at 9 sites Xijing Hospital · Lanzhou, Gansu and 8 other locations · NCT07553754

• Hospital admissions for blood in the urine

  This international observational project will look at how hospitals manage adults admitted with blood in the urine to see which approaches lead to shorter stays and better outcomes.

  Recruiting British Urology Researchers in Surgical Training · London · NCT07395037

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.